Biographical Info

SAJE Pharma is a private, biopharmaceutical company focused on the development of novel GSNOR inhibiting drugs for diseases driven by inflammation, oxidant damage, and fibrosis, including: idiopathic pulmonary fibrosis, rheumatoid arthritis, cardiovascular diseases, NASH, and cancers. SPL-891.1 is in preclinical development for an IND submission for NASH. SAJE’s other drugs are in research for COPD, RA, cancer, and cardiovascular diseases. SAJE started operations in 2011 and now has four employees and a wide range of academic and CRO collaborators.